Very critical month (November 2):
Key Highlights and Upcoming Milestones:
U.S. FDA acceptance of the New Drug Application (NDA) for Talicia® for H. pylori
for priority review and assignment of a target PDUFA action date of November 2,
2019
• Preparations ongoing for the potential U.S. commercial launch of Talicia® in Q4/2019,
subject to FDA approval, with RedHill’s established sales force, led by the Company’s
experienced commercial management team
• FDA meetings planned to take place in H2/2019 to discuss the path to potential
approval of RHB-104 for Crohn’s disease
• Initiation of pivotal Phase 3 study activities with RHB-204 for first-line treatment of
pulmonary nontuberculous mycobacteria (NTM) infections expected in Q4/2019
• Debt-free balance sheet with $34.9 million cash balance as of June 30, 2019
All of the above at your discretion, your accepted trading rules, trading strategies and your preferred trading management.
This is not a recommendation to buy or sell.
Key Highlights and Upcoming Milestones:
U.S. FDA acceptance of the New Drug Application (NDA) for Talicia® for H. pylori
for priority review and assignment of a target PDUFA action date of November 2,
2019
• Preparations ongoing for the potential U.S. commercial launch of Talicia® in Q4/2019,
subject to FDA approval, with RedHill’s established sales force, led by the Company’s
experienced commercial management team
• FDA meetings planned to take place in H2/2019 to discuss the path to potential
approval of RHB-104 for Crohn’s disease
• Initiation of pivotal Phase 3 study activities with RHB-204 for first-line treatment of
pulmonary nontuberculous mycobacteria (NTM) infections expected in Q4/2019
• Debt-free balance sheet with $34.9 million cash balance as of June 30, 2019
All of the above at your discretion, your accepted trading rules, trading strategies and your preferred trading management.
This is not a recommendation to buy or sell.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.